A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease

Trial ID or NCT#

NCT02160145

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD).

Investigator(s)

Richard Lafayette, MD

View on ClinicalTrials.gov